{
  "symbol": "IMNM",
  "company_name": "Immunome Inc",
  "ir_website": "https://investors.immunome.com/",
  "structured_data": [
    {
      "section_name": "Latest News",
      "links": [
        {
          "title": "Immunome to Present at the Piper Sandler 36th Annual Healthcare Conference",
          "url": "https://investors.immunome.com/immunome-to-present-at-the-piper-sandler-36th-annual-healthcare-conference/",
          "content": ""
        },
        {
          "title": "Immunome Reports Third Quarter 2024 Financial Results and Provides Business Update",
          "url": "https://investors.immunome.com/immunome-reports-third-quarter-2024-financial-results-and-provides-business-update/",
          "content": ""
        },
        {
          "title": "Immunome to Present at Guggenheim’s Inaugural Healthcare Innovation Conference",
          "url": "https://investors.immunome.com/immunome-to-present-at-guggenheims-inaugural-healthcare-innovation-conference/",
          "content": ""
        },
        {
          "title": "Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
          "url": "https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2/",
          "content": ""
        },
        {
          "title": "Immunome Presents Compelling Preclinical Data Demonstrating Robust Anti-Tumor Activity for IM-1021",
          "url": "https://investors.immunome.com/immunome-presents-compelling-preclinical-data-demonstrating-robust-anti-tumor-activity-for-im-1021/",
          "content": ""
        },
        {
          "title": "Immunome to Present Poster Highlighting Preclinical Evaluation of IM-1021, a ROR1-Targeted Antibody Drug Conjugate, at the 36th EORTC-NCI-AACR Symposium",
          "url": "https://investors.immunome.com/immunome-to-present-poster-highlighting-preclinical-evaluation-of-im-1021-a-ror1-targeted-antibody-drug-conjugate-at-the-36th-eortc-nci-aacr-symposium/",
          "content": ""
        },
        {
          "title": "Immunome Appoints Roee Shahar as Executive Vice President, Commercial",
          "url": "https://investors.immunome.com/immunome-appoints-roee-shahar-as-executive-vice-president-commercial/",
          "content": ""
        },
        {
          "title": "Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)",
          "url": "https://investors.immunome.com/immunome-reports-inducement-grants-under-nasdaq-listing-rule-5635c4/",
          "content": ""
        },
        {
          "title": "Immunome to Present Updated Results for RINGSIDE Phase 2 Trial of AL102 for the Treatment of Desmoid Tumors at the European Society for Medical Oncology (ESMO) Congress 2024",
          "url": "https://investors.immunome.com/immunome-to-present-updated-results-for-ringside-phase-2-trial-of-al102-for-the-treatment-of-desmoid-tumors-at-the-european-society-for-medical-oncology-esmo-congress-2024/",
          "content": ""
        },
        {
          "title": "Immunome to Present at Morgan Stanley 22nd Annual Global Healthcare Conference",
          "url": "https://investors.immunome.com/immunome-to-present-at-morgan-stanley-22nd-annual-global-healthcare-conference/",
          "content": ""
        }
      ]
    },
    {
      "section_name": "Latest Presentations",
      "links": [
        {
          "title": "Immunome Corporate Presentation",
          "url": "https://investors.immunome.com/wp-content/uploads/2024/11/Immunome-Corporate-Presentation-November-2024.pdf",
          "content": "Immunome Corporate\nPresentation\nNovember 2024\nDisclaimer and Forward-Looking Statements\nDisclosures\nFor thepurposes of this notice, the “presentation”that follows shallmean and include the slides that follow, anyoral presentation of theslides bymembers ofmanagement ofImmunome, Inc. (“Immunome”)or any\nperson on its behalf, any question-and-answer session that follows that oral presentation, hard copies of this document and any materials distributed at, or in connection with, that presentation. References to “we,”\n“our,”and“us”referstoImmunomeanditssubsidiaries.ThispresentationshallnotconstituteanoffertosellorthesolicitationofanoffertobuyanyImmunomesecurities\nForward-LookingStatements\nStatementsinthispresentationthatarenotpurelyhistoricalinnatureare“forward-lookingstatements”withinthemeaningofthePrivateSecuritiesLitigationReformActof1995.Weusewordssuchas“may,”“might,”\n“will,”“could,”“would,”“should,”“expect,”“intend,”“plan,”“vision,”“objective,”“anticipate,”“believe,”“estimate,”“predict,”“potential,”“continue,”“promising,”“projected,”“firststep,”“ongoing,”orthenegativeofthese\nterms, and similar words or expressions to identify these forward-looking statements. These forward-looking statements include, but are not limited to, statements about: the expansion and advancement of our\nplatform and pipeline and our approach and strategy related to the platform and pipeline; assessments of the clinical efficacy, best-in-class potential, and potential commercial success of our AL102 program; the\npotentialofourcurrentandfuturepipelinetoproducefirst-in-classand/orbest-in-classdrugs;ourexpectationswithrespecttofutureperformance,anticipatedfinancialimpacts,abilitytocompleteandsuccessofour\nstrategic transactions; our timeline for filing INDs and other regulatory filings, and seeking regulatory approval, for one or more of our current or future programs and product candidates and other anticipated\nmilestones;ourexpectedcashrunway;ourabilitytoexpandourplatformandestablishabroadpipelineandadvanceitthroughefficientclinicaldevelopmentdecisions;ourintentiontocontinueexpandingourpipeline\nthroughstrategic transactions;ourintent to expandourintellectualpropertyportfolio;andotherstatements regardingmanagement’s intentions,plans,beliefs, expectationsor forecasts forthefuture. These forward-\nlooking statements are based on Immunome’s current expectations and involve assumptions that may never materialize or may prove to be incorrect; consequently, actual results may differ materially from those\nexpressed or implied in the statements due to a number of factors, including, but not limited to, the risk that Immunome will not be able to realize the benefits of its strategic transactions; the risk that regulatory\napprovals forImmunome’s programsandproduct candidates are not obtained, are delayed oraresubject to unanticipatedconditions; the risk that pre-clinicaldata maynotbepredictive of clinical data;therisk that\nImmunome’s product candidates and development candidates fail to achieve their intended endpoints; the reliance on Immunome’s management; the prior experience and successes of Immunome’s management\nteam not being indicative of any future success; uncertainties related to Immunome’s capital requirements and Immunome’s expected cash runway; Immunome’s ability to grow and successfully execute on its\nbusiness plan, including the development and commercialization of its pipeline and integration of newly acquired assets; and other risks and uncertainties indicated from time to time described in Immunome’s\nQuarterlyReportonForm10-QforthequarterendedMarch31,2024,filedwiththeSEConMay14,2024,inImmunome’sQuarterlyReportonForm10-QforthequarterendedJune30,2024,filedwiththeSECon\nAugust 12, 2024, and in Immunome’s other filings with the SEC. Except as required by law, Immunome assumes no obligation and does not intend to update any forward-looking statements included in this\npresentation.\nProductCandidates\nIn this presentation, we may discuss current and potential future product candidates that have not yet undergone clinical trials or been approved for marketing by the U.S. Food and Drug Administration or other\ngovernmentalauthority.Norepresentationismadeastothesafetyoreffectivenessofthesecurrentorpotentialfutureproductcandidatesfortheuseforwhichsuchproductcandidatesarebeingstudied.\nIndustryandMarketData\nInthispresentation,werelyonandrefertopubliclyavailableinformationandstatisticsregardingmarketparticipantsinthesectorsinwhichwecompeteandotherindustrydata.Anycomparisonofustotheindustryor\nto any of our competitors is based on this publiclyavailable information and statistics and such comparisons assume the reliability of the information available to us.Weobtained this information and statistics from\nthird-party sources, including reports by market research firms and company filings. While we believe such third-party information is reliable, there can be no assurance as to the accuracy or completeness of the\nindicatedinformation.Wehavenotindependentlyverifiedtheinformationprovidedbythethird-partysources.\nTrademarks\nThispresentationmaycontaintrademarks,servicemarks,tradenamesandcopyrightsofothercompanies,whicharethepropertyoftheirrespectiveowners.Solelyforconvenience,someofthetrademarks,service\nmarks,tradenamesandcopyrightsreferredtointhispresentationmaybelistedwithouttheTM,SM©or®symbols,butwewillassert,tothefullestextentunderapplicablelaw,therightsoftheapplicableowners,if\nany,tothesetrademarks,servicemarks,tradenamesandcopyrights.\nCONFIDENTIAL -DO NOT DISTRIBUTE 2\nEstablishing a Premier ADC Company\nStrong Foundation for Long-Term Success\nExperienced, Fully enrolled Phase 3 trial of AL 102 for the Cash runway\nsuccessful leadership treatment of desmoid tumors expected to extend\nteam with record of into 2026 following\ndesigning, developing, recent financings\nand commercializing in February 2024\nADCs and other ($230M) and\ntargeted oncology Target-driven ADC October 2023\ntherapies strategy with broad ($125M)\ntoolbox\nTwo preclinical programs with first-in-class\nor best-in-class potential:\n• IM-1021: ROR1 antibody-drug conjugate (ADC)\n• IM-3050: FAP radioligand therapy (RLT)\nHeadquarters in Bothell, WA\nCONFIDENTIAL -DO NOT DISTRIBUTE 3\nLong-Term Corporate Vision\nDevelop differentiated Robust internal discovery Additional platform and\nADCs with a focus on efforts pipeline expansion driven by\nfirst-in-class targets disciplined M&A\nAdvance pipeline through Strong biotech investor Strategic partnering to access\nefficient clinical development syndicate supportive of non-dilutive capital\ncorporate vision\nCONFIDENTIAL -DO NOT DISTRIBUTE 4\nManagement Team with a Demonstrated Track Record of Success\nClay Siegall, Ph.D. • Chief Executive Officer and Founder, Seagen (1998-2022)\nPRESIDENT & • Grew company to $2B+ revenue (2022) leading to $43B acquisition\nCHIEF EXECUTIVE OFFICER\n• Led development of 4 FDA-approved therapeutics\n• Raised over $1B in public and private capital\n• Oversaw acquisition and integration of Cascadian Therapeutics\n• Generated >$3B in partnership and licensing revenue\nJack Higgins, Ph.D. Kinney Horn Bob Lechleider, M.D. Max Rosett\nCHIEF SCIENTIFIC OFFICER CHIEF BUSINESS OFFICER CHIEF MEDICAL OFFICER CHIEF FINANCIAL OFFICER\nRoee Shahar Sandra Stoneman Phil Tsai Bruce Turner, M.D., Ph.D.\nEVP, COMMERCIAL CHIEF LEGAL OFFICER CHIEF TECHNICAL OFFICER CHIEF STRATEGY OFFICER\nCONFIDENTIAL -DO NOT DISTRIBUTE 5\nPipeline Overview\nCandidate Mechanism of Action Discovery Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone\nPhase 3 Topline\nAL102 Gamma Secretase Inhibitor\n2H25\nIND Submission\nIM-1021 ROR1 ADC\n1Q25\nIND Submission\nIM-3050 FAP RLT\n1Q25\nCandidate Nomination\n- Undisclosed ADCs\nTBD\nIM-1021 was formerly known as ZPC-21.\nCONFIDENTIAL -DO NOT DISTRIBUTE 6\nRecent Business Development Activity Expanded Pipeline and\nToolbox With Moderate Investment\n4 Antibodies\n2024\nAL102 and AL101\nMarch 2024\n28 Antibodies\nMay 2024\nPRECLINICAL CLINICAL\nCONFIDENTIAL -DO NOT DISTRIBUTE 7\nSNOITCASNART\nTNECER\nAntibody\n2024\nIM-1021 &\nUnderlying ADC\nPlatform\nJanuary 2024\nAntibody\n2024\nTOOLBOX TECHNOLOGY\nADC Strategy\nCONFIDENTIAL -DO NOT DISTRIBUTE 8\nSystematically Evaluate Novel Targets for First-in-Class ADC\nPotential\nSources of Novel Targets and Antibodies\nImmunome Discovery Platform\n>30 identified targets\nLicensing/Acquisition\n>25 antibodies from Atreca\nExpression Screening\nPublic and proprietary databases\nCONFIDENTIAL -DO NOT DISTRIBUTE 9\nnoisserpxE\nromuT\nTargets are evaluated for differential tumor\nexpression and additional considerations\nSolid Tumor ADCs\nTivdak\nTrodelvy\nElahere\nEnhertu,\nPadcev Kadcyla\nApproved Drugs\nClinical Stage Programs\nImmunome Internal Targets\nNormal Tissue Expression\nProprietary Payload Provides Opportunity to Develop\nBest-in-Class ADCs\nHC74 is a novel camptothecin derivative that\nHC74 has improved properties compared to DXd\npotently drives TOP1 inhibition\nClearance1 Efflux2 Permeability3 Cytotoxicity4\n• Same mechanism as Enhertu’s payload (deruxtecan/DXd)\nDXd >216 min 79 8 20 nM\nHC74 retains the validated TOP1 mechanism of HC74 82 min 10 21 5 nM\naction while showing properties superior to DXd\n1.Human hepatocyte clearance, T1/2 (min); 2. Caco-2 efflux ratio; 3. PAMPA permeability (x10-6cm/s); 4.Median IC50 (nM)\n• Greater in vitro potency\nHC74 retains efficacy in chemo-resistant cell lines\n• Retains activity in chemo-resistant cell lines\nIC50 (nM)\n• Increased permeability may lead to superior bystander effect\nCell line Description\nFold\nHC74 DXd\n• Faster clearance may improve tolerability after cleavage Difference\nH69 Parental 3.0 7.4 2.5\nDoxorubicin-\nH69/AR 1.8 21 11.7\nresistant\nVincristine-\nH69/VCR 2.9 33 11.4\nresistant\nCONFIDENTIAL -DO NOT DISTRIBUTE 10\nCamptothecin Derivatives Are Well-Suited for ADCs Targeting Solid\nTumors\nADCs Containing Camptothecins Achieve Higher Enhertu (With Camptothecin Derivative Payload)\nDARs and Higher Clinical Doses Outperforms Kadcyla in Breast Cancer3\n12\n10\n8\n6\n10\n4\n5.4\n2 3.6\n1.8 1.25 2 2.5\n0\nPolivy® Padcev® Tivdak® Kadcyla® MK-2140 Enhertu® Trodelvy®\nCONFIDENTIAL -DO NOT DISTRIBUTE 11\n)gk/gm(\nesod\nlacinilC\nClinical Doses of Selected ADCs1\nPayload MOA\nMicrotubule Inhibitor\nTOPO1 Inhibitor (TOPO1i)\n10\n8\n6\n• Enhertu and Kadcyla are both trastuzumab ADCs\n4 8 7.6 • Enhertu’spayload, deruxtecan, allows for higher DAR and higher\n2 3.5 3.8 4 3.5 4 clinical dosage\n• Clinical data shows Enhertu is more effective, notably in HER2-\n0\nPolivy® Padcev® Tivdak® Kadcyla® MK-2140 Enhertu® Trodelvy® low patients\nRAD\nProgression-Free Survival\nEnhertu\n(Trastuzumab deruxtecan)\nn=261\nKadcyla\n(Trastuzumab emtansine)\nDrug-Antibody Ratios of Selected ADCs2 n=263\nPayload MOA\nMicrotubule Inhibitor\nTOPO1 Inhibitor (TOPO1i)\n1. Respective drug labels or FDA guidance 2. Tong JTW, Harris PWR, Brimble MA, KavianiniaI. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2021 Sep 27;26(19):5847. doi: 10.3390/molecules26195847. PMID: 34641391; PMCID:\nPMC8510272. 3. Cortés et. al. N EnglJ Med (2022); 386:1143-1154\nstneitap\nfo\negatnecreP\nStrong Demand for ADCs Provides Strategic Flexibility\nOpportunities to Transact at Value Inflection Points\n$2B TOTAL1 $170M UPFRONT3 $4B UPFRONT\n$1.5B+ IN MILESTONES $22B IN MILESTONES5\n$43B\nACQUISITION7\n$175M UPFRONT $85M UPFRONT4 $2B ACQUISITION6\n$9.3B2 $1.4B\nIN MILESTONES IN MILESTONES\nPRECLINICAL EARLY CLINICAL LATE CLINICAL COMMERCIAL\n1. https://synaffix.com/synaffix-enters-license-agreement-with-amgen-to-build-next-generation-adcs 2.. https://www.biospace.com/article/merck-expands-adc-footprint-with-9-3b-kelun-licensing-deal 3. https://www.globenewswire.com/news-release/2023/04/03/2639380/0/en/BioNTech-and-DualityBio-Form-Global-Strategic-Partnership-to-Accelerate-Development-of-Differentiated-Antibody-Drug-\nConjugate-Therapeutics-for-Solid-Tumors.html 4. https://www.fiercebiotech.com/biotech/2nd-big-adc-deal-day-gsk-inks-2b-pact-hansoh-gynecology-cancer-asset 5. https://www.fiercebiotech.com/biotech/merck-pays-4b-upfront-rights-3-daiichi-adcs-huge-bet-post-keytruda-future 6. https://www.globenewswire.com/news-release/2024/01/08/2805344/0/en/Ambrx-Announces-Sale-to-Johnson-\nJohnson.html7. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-43-billion-battle-cancer\nCONFIDENTIAL -DO NOT DISTRIBUTE 12\nSNOITCASNART\nCDA\nTNECER\nAL102\nCONFIDENTIAL -DO NOT DISTRIBUTE 13\nHigh Unmet Need for Patients with Desmoid Tumors\nDesmoid Tumors Are Debilitating, Painful, and Gamma Secretase Inhibitors For Treatment of\nAggressive Desmoid Tumors\n• Gamma secretase inhibitors (GSIs) block the NOTCH\n~1,000-1,650 ~5,500-7,000\npathway, a driver of desmoid tumors\nPatients diagnosed Actively managed patients\nannually in the US1 in the US2 • OGSIVEO (nirogacestat), a GSI from Springworks, was\napproved in November 2023 for treatment of desmoid tumors\n• Painful soft tissue tumors that can lead to serious disability\nwhen left untreated\n• Highest incidence in young adults, with women at greater risk\nthan men\n• Until 2023, no approved systemic therapy; local therapies are\ndebilitating and have a high risk of recurrence\n• Reversing tumor growth, alleviating pain, and preventing\ntherapeutic complications are key components of therapeutic\nintervention\n1. Gounder2023 doi: 10.1007/s11136-023-03445-7 2. Tsukamoto 2022 doi: 10.1007/s12306-022-00738-x\nCONFIDENTIAL -DO NOT DISTRIBUTE 14\nAL102 Data With Daily Dosing Shows Increased Response\nCompared to Nirogacestat Across All Measures\nORR by RECIST\n• AL102 is being evaluated as an oral, once-\nEvaluable\ndaily GSI for the treatment of desmoid tumors\nAL102 1.2mgQD1\n75% ITT\nMedianToT16.6months\n• Phase 2 RINGSIDE data has shown deep,\n64%\ndurable responses and an opportunity to Nirogacestat150mgBID2,3\nMedianToT20.6months\nestablish new standard of care, if approved\n44%\n41%\n• Reduced T2 imaging suggests reduced\ncellularity\nTumorVolume T2 Imaging\n• Safety profile consistent with GSI class N=12 N=66 N=14 N=70 (medianbest, evaluable) (medianbest, evaluable)\nN=12 N=61 N=12 N=53\n• Phase 3 RINGSIDE trial fully enrolled, with\nadditional NDA-enabling work underway FOR ILLUSTRATIVE PURPOSES ONLY: no head-to-head clinical trial has been\nconducted evaluating AL102 against nirogacestat or other candidates or products.\nDifferences exist between trial designs and subject characteristics, and strong\ncaution should be exercised when comparing data across unrelated studies.\n-55%\n-59%\n-85%\n-88%\n1 KasperBetal.,ESMOCongress2023_1929P (Cutoff Date –July 5, 2023) One patient previously reported as PR at ESMO subsequently progressed prior to response confirmation. 2. GounderMetal.,NEJM2023, 388:898 3. AlcindorT.,etal.,ASCOAnnualMeeting 2023,Abstract#11514 EvaluablePopulation\nCONFIDENTIAL -DO NOT DISTRIBUTE 15\nSafety in Phase 2 Portion of RINGSIDE is consistent with GSI class\nStudy Population, n(%) AL102, 1.2mg QD, (n=14) Nirogacestat 150mg BID (n=69)\nAny Grade Grade ≥3 Any Grade Grade ≥3\nDiarrhoea 13 (92.8) 2 (14.3) 58 (84) 11 (16)\nNausea 8 (57.1) – 37 (54) 1 (1)\nFatigue 7 (50) – 35 (51) 2 (3)\nAlopecia 7 (50) – 13 (19) –\nDry skin 7 (50) – 11 (16) –\nStomatitis 7 (50) 1 (7.1) 20 (29) 3 (4)\nDermatitis acneiform 6 (42.9) – 15 (22) –\nDry mouth 6 (42.9) – NR NR\nHypophosphatemia 6 (42.9) – 29 (42) 2 (3)\nRash maculo-papular 5 (35.7) – 22 (32) 4 (6)\nAspartate aminostransferase increased 4 (28.6) – 11 (16) –\nMonths on the study (mean, range), months 16.6 (1-21.6) 20.6 (0.3 –33.6)\nOvarian dysfunction in pre-menopausal women: 5/9 (55.6%) with AL102 in 1.2 mg QD arm versus 27/36 (75.0%) in Niro DeFi Study\nFOR ILLUSTRATIVE PURPOSES ONLY: no head-to-head clinical trial has been conducted evaluating AL102 against nirogacestat or othercandidates or products. Differences exist between trial designs and subject characteristics, and strong caution should be exercised when comparing data across unrelated studies.\n1 KasperBetal.,ESMOCongress2023_1929P (Cutoff Date –July 5, 2023) 2. GounderMetal.,NEJM2023, 388:898 3. AlcindorT.,etal.,ASCOAnnualMeeting 2023,Abstract#11514 EvaluablePopulation\nCONFIDENTIAL -DO NOT DISTRIBUTE 16\nRINGSIDE study design: Phase 3\nPART B\nKey Inclusion Criteria Endpoints\n•Relapsed/refractory or treatment- •Primary: PFS\nnaïve, with PD (per RECIST)\n•Secondary: ORR & DOR by BICR,\nin last 12 months\nPROs, Safety\n•Age ≥12\n•Exploratory: MRI T1 & T2, ORR &\n•Measurable Lesion or MRI or CT DOR by investigator, PK, Biomarkers\nOLE\nKey Inclusion Criteria Endpoints\n•Participating in Part B and were •Primary: Safety\nnoted to have progressive disease\n•Secondary: PFS, ORR & DOR by\nby central review\nBICR, PROs\n•Still on study after completion of\n•Exploratory: PK\nCrossover has no observed impact on statistical analysis Part B\nof primary endpoint\nCONFIDENTIAL -DO NOT DISTRIBUTE 17\nPrograms: ROR1 ADC\nCONFIDENTIAL -DO NOT DISTRIBUTE 18\nROR1 Is a Clinically Validated ADC Target\nROR1 MK-2140 Objective Response Rate In Three\nPretreated Lymphoma Indications\n• Receptor with oncofetal expression pattern1\n• Little or no expression in healthy tissue\n• Expressed on solid and liquid tumors 60%\n50% 14%\n12%\nMK-2140\n40%\n• MK-2140 (formerly known as VLS-101) is a ROR1-targeted\nADC 30%\n• Merck acquired Velos Bio for $2.75 billion to obtain VLS-101 20% 18% 41% 43%\n• Currently being evaluated in four phase 2 trials for\n10%\nB-cell malignancies\n12%\n0%\n• Development for solid tumors discontinued after Phase 2\nDiffuse Large B-Cell Mantle Cell Richter's\nLymphoma Lymphoma Transformation\n(n=17) (n=17) (n=7)\nCONFIDENTIAL -DO NOT DISTRIBUTE 19\nRRO\nPR CR\n1. Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, Mellstedt H. The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol. 2014 Dec;29:21-31. doi: 10.1016/j.semcancer.2014.07.005. Epub 2014 Jul 25. PMID: 25068995 2.Wang, et al. HematOncol, 41:S2, Lugano\nLymphoma Conference Supplement Supplement: 17th International Conference on Malignant Lymphoma, 13 17 June, 2023\n‐\nSignificant Opportunity for ROR1 in Solid Tumors\nPotential ROR1 indications include diseases with ROR1 target biology presents challenges to\nlarge patient population and high unmet need developing a successful ADC for ROR1 positive\n100% solid tumors\n90%\n• Moderate to low expression levels\n80%\n• Slow internalization\n70%\n60%\nApproach to overcome challenges\n50%\n• Select antibody that promotes internalization\n40%\n30%\n• Design linker-payload for improved therapeutic index, allowing\n20% for higher clinical dose\n10%\n• Use payload that maximizes bystander effect and supports\n0%\ndrug-antibody ratio (DAR) of 8\n1. Wang, et al. HematOncol, 41:S2, Lugano Lymphoma Conference Supplement Supplement: 17th International Conference on Malignant Lymphoma, 13 17 June, 2023\n‐\nCONFIDENTIAL -DO NOT DISTRIBUTE 20\n)441=n(\nnairavO\n)011=n(\nnoloC\n)46=n(\ngnuL\n)85=n(\namohpmyL\n)55=n(\nnikS\n)75=n(\ncitaercnaP\n)84=n(\nralucitseT\n)04=n(\nreddalB\n)92=n(\nsuretU\n)12=n(\netatsorP\n)21=n(\nlanerdA\nPercent of\nROR1\nPositive\nNegative\nModerate\nStrong\nIM-1021 is a ROR1 ADC with Potential for Improved Therapeutic Index\nZilovertamabVedotin(MK-2140 / VLS-101)\nMC-VC-PAB MMAE: Tubulin Inhibitor Phase 2 completed;\nno further updates Cysteine conjugation\nCleavable through Val-Cit\nDAR 4\nNBE-002\nPeptide linker containing GGGG PNU (Anthracycline derivative): Discontinued\nH O H O H O OH O DNA intercalator\nN N N Sortase-mediated conjugation\nHN O N H O N H O N HHO P (aN nU th-1 ra5 c9 y6 c8 l2 in e\nLPET O N O OH O OMe derivative) Cleavable\nsortase mediated MeO O O\nsite-specific bioconjugation DAR 4\nCO2H\nCS5001 (LCB71) O OO OO HH Glucuronidase cleavable linker Pyrrolobenzodiazepine Phase 1 Ongoing\nHN OH (PBD-dimer) prodrug: DNA\nMeO OHO H Farnesyltransferase conjugation\nCO2H O N crosslinker\nO OO O OH H O ON Cleavable\nS NO O 5NH OH MeO\nO O DAR 2\nFarnesyltransferase mediated OHO N OMe PBD dimers\nsite-specific bioconjugation H\nN O\nIM-1021 (Formerly ZPC-21)\nUndisclosed linker CamptothecinDerivative: IND expected 1Q 2025\nCysteine conjugation Topoisomerase I inhibitor\nStructure Omitted\nCleavable\nDAR 8\nCONFIDENTIAL -DO NOT DISTRIBUTE 21\nMIVC\nName Linker / DAR Payload Development Status\nEt O O H N O N H N OH\nH S N O H N O O N O N OMeO OMeO\nN N\nO H O H\nUC961 Monomethyl Auristatin E (MMAE)\ncysteine random NH\nO NH2\nIM-1021 Shows Sustained Tumor Regression in TNBC Mouse Model\nIM-1021 Inhibits Tumor Growth in MDA-MB-468\nModel (Triple Negative Breast Cancer)\n1200\n800\n400\n0\n0 7 14 21 28 35 42 49\nDays Post Treatment Initiation\nCONFIDENTIAL -DO NOT DISTRIBUTE 22\n3\n)\nmm(\nemuloV\nromuT\nIM-1021 demonstrates superior activity compared to MK-2140 at each respective dose\nNo Weight Loss Observed\n30\nVehicle qw × 3\nATX875-1-5379 (2.5 mg/kg qw×3) 20\nATX875-1-5379 (5.0 mg/kg qw×3)\nVLS-101 (2.5 mg/kg qw×3) 10\nVLS-101 (5.0 mg/kg qw×3)\n0\n-10\n-20\n-30\n0 7 14 21 28 35 42 49\nDays Post Treatment Initiation\nDose QWx3, i.v.\negnahC\nWB\n%\nClinical Development Plan: Rapid Evaluation of Clinical PoC\nFollowed by Pivotal Studies Across Multiple Indications\nPivotal Clinical Studies\nSolid tumor expansion\nIndications including NSCLC, breast Criteria for selecting indications:\ncancer, prostate cancer, pancreatic\ncancer, and gastric cancer1 • Compelling Phase 1 clinical outcomes\nRapid dose escalation in • Significant commercial opportunities\nsolid tumors and lymphoma\n• Enhanced outcomes with companion\ndiagnostic\nB-cell malignancy expansion\nDiffuse large B-cell lymphoma, mantle • Potential for Accelerated Approval\ncell lymphoma\nNon-clinical evaluation of combination therapies, particularly in B-cell malignancies\nCompanion diagnostic development and evaluation\n1. Clinical development plan subject to further refinement and addition or removal of indications.. NSCLC = non-small cell lung cancer\nCONFIDENTIAL -DO NOT DISTRIBUTE 23\nPrograms: FAP RLT\nCONFIDENTIAL -DO NOT DISTRIBUTE 24\nFAP Is a Promising RLT Target with Pan-Cancer Potential\nFibroblast Activation Protein (FAP) is a cell surface FAP imaging shows high expression across\nprotease with low expression in normal tissue 15 distinct tumor types\n• FAP is overexpressed on cancer-associated fibroblasts, the\nmost common tumor stromal cell, with expression in 75% of\nsolid tumors\n• FAP-Lu radioligand therapy delivers radioactive 177Lu directly\nto FAP-expressing cells, with bystander effect targeting tumor\ncells\n• RLT approach expected to overcome limitations that make FAP\nunsuitable for ADCs (poor internalization and low expression on\ntumor cells)\nSource: Kratochwil C, Flechsig P, Lindner T, et al.68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.J Nucl Med.2019;60(6):801-805.\nCONFIDENTIAL -DO NOT DISTRIBUTE 25\nImmunome 177Lu-FAP Candidates are Rationally Designed and\nSystematically Screened\nImmunome has systematically Immunome Approach\nselected a ligand, linker, albumin\nExample Structure: Proven structure used by\nPluvicto and Lutathera to\nbinding domain, and payload to\nOptimized linker deliver Lu-177 isotope\noptimize: reduces non-specific\nuptake\nFAP Ligand Chelator\n• Binding and specificity\nLinker\n• Stability\n• Pharmacokinetics\n• Tumor absorbed dose\n• Efficacy\nAlbumin Binder\n• Tolerability\nFAP binding Albumin binding domain selected to\nand specificity optimized maximize tumor retention\nOptimized ligand potentially leads to: Incorporating albumin binder potentially\n• Increased tumor uptake and retention extends circulating half-life and increases\ntumor residence time, leading to superior\n• Superior efficacy\ntumor absorbed dose in vivo\n• Stability and ease of manufacture\nCONFIDENTIAL -DO NOT DISTRIBUTE 26\nIncorporating Albumin Binders into Radioligand Therapies\nImproves In Vivo PK Profile and Biodistribution\nTotal Absorbed Dose Rat IV PK\n600 Albumin Binding\n500 Weak\nModerate\n400 Strong\n300\n200\n100\n0\nLiver Kidneys Tumor\nLeft panel: unpublished preclinical biodistribution data in 4T1 mouse tumor model. Right panel: Single dose (1 mg/kg) iv ratPKstudy.\nCONFIDENTIAL -DO NOT DISTRIBUTE 27\nqBM/yGm\n100000\n10000\n1000\n100\n10\n1\n0.1\n0 20 40 60\nTime (h)\nnoitartnecnoc\namsalP\nnoitartnecnoc\namsalP\n)Lm/gn(\n)Lm/gn(\nEnhanced pharmacokinetics may lead to superior tumor absorbed dose\nAlbumin Binding\nWeak\nModerate\nStrong\nTime (Hours)\nIM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential\nTumor Regression in U87MG Model\nNo Weight Loss Observed Potential Best-in-Class Characteristics\n• Sub-nanomolar affinity\n• High specificity\n1500%\n• Radiostability\n• Superior tumor retention and tumor\nabsorbed dose in vivo\n1000%\n• Preclinical activity and tolerability\n500%\n0%\n0 3 6 9 12 15 18 21 24 27\nDay\nDEVELOPMENT STATUS:\n✓ ✓\nIn Vivo Radiotherapy Clinical Formulation IND filing\nGLP/GMP Manufacturing Prepare IND package\nStudies Development anticipated 1Q25\nCONFIDENTIAL -DO NOT DISTRIBUTE 28\nemulov\nromut\nevitaleR\n177 Lu-Mi-003 Radiotherapy in U87MG tumors\nVehicle\nUndisclosed Candidate #1 (High Lu-177 Dose)\nUndisclosed Candidate #1 (Low Lu-177 Dose)\nUndisclosed Candidate #1 (High Lu-177 Dose)\n120% Undisclosed Candidate #1 (Low Lu-177 Dose)\n110%\n100%\n90%\n80%\n70%\n0 3 6 9 12 15 18 21 24 27\nDay\nthgiew\nydob\nevitaleR\nIn vivo data show single dose antitumor activity and tolerability\n177\nLu-Mi-003 Radiotherapy in U87MG tumors\nVehicle VVeehhicilcele\nIM-3047, High Lu-177 Dose IUMn-d3is0cl4os7e,d HCaigndhid Latue- #117 (7H igDho Lsu-e177 Dose)\nIM-3047, Low Lu-177 Dose IUMn-d3is0cl4os7e,d LCoanwd idLaute- 1#71 7(L oDwo Lsue-177 Dose)\nIM-3050, High Lu-177 Dose IUMn-d3is0cl5os0e,d HCaigndhid Latue- #127 (7H igDho Lsu-e177 Dose)\nIM-3050, Low Lu-177 Dose IUMn-d3is0cl5os0e,d LCoanwd idLaute- 1#72 7(L oDwo Lsue-177 Dose)\n✓\nBuilding the Foundation of a Premier ADC Company\nExperienced management team with headquarters in Bothell, WA\nFully enrolled Phase 3 trial for AL102 for the treatment of desmoid tumors\nTwo preclinical programs with best-in-class or first-in-class potential:\n• IM-1021: ROR1 ADC\n• IM-3050: FAP RLT\nOpportunities for platform-driven pipeline expansion including next-generation ADCs and RLTs\nPipeline and toolbox expansion through disciplined M&A including recent purchase of AL102 from Ayala and exclusive\nlicense agreement with Zentalis\nCash runway expected to extend into 2026 and fund key clinical inflection points following recent financings in February\n2024 ($230M) and October 2023 ($125M)\nCONFIDENTIAL -DO NOT DISTRIBUTE 29"
        },
        {
          "title": "Immunome Corporate Presentation (August 2024)",
          "url": "https://investors.immunome.com/wp-content/uploads/2024/08/Immunome-Corporate-Presentation-August-2024.pdf",
          "content": "Immunome Corporate\nPresentation\nAugust 13, 2024\nDisclaimer and Forward-Looking Statements\nDisclosures\nForthepurposesofthisnotice,the“presentation”thatfollowsshallmeanandincludetheslidesthatfollow,anyoralpresentationoftheslidesbymembersofmanagementofImmunome,Inc.(“Immunome”)oranypersononitsbehalf,anyquestion-and-answersessionthat\nfollowsthatoralpresentation,hardcopiesofthisdocumentandanymaterialsdistributedat,orinconnectionwith,thatpresentation.Referencesto“we,”“our,”and“us”referstoImmunomeanditssubsidiaries.Thispresentationshallnotconstituteanoffertosellorthe\nsolicitationofanoffertobuyanyImmunomesecurities\nForward-LookingStatements\nStatementsinthispresentationthatarenotpurelyhistoricalinnatureare“forward-lookingstatements”withinthemeaningofthePrivateSecuritiesLitigationReformActof1995.Weusewordssuchas“may,”“might,”“will,”“could,”“would,”“should,”“expect,”“intend,”“plan,”\n“vision,”“objective,”“anticipate,”“believe,”“estimate,”“predict,”“potential,”“continue,”“promising,”“projected,”“firststep,”“ongoing,”orthenegativeoftheseterms,andsimilarwordsorexpressionstoidentifytheseforward-lookingstatements.Theseforward-lookingstatements\ninclude,butarenotlimitedto,statementsabout:theexpansionandadvancementofourplatformandpipelineandourapproachandstrategyrelatedtotheplatformandpipeline;assessmentsoftheclinicalefficacy,best-in-classpotential,andpotentialcommercialsuccessof\nourAL102program;thepotentialofourcurrentandfuturepipelinetoproducefirst-in-classand/orbest-in-classdrugs;ourexpectationswithrespecttofutureperformance,anticipatedfinancialimpacts,abilitytocompleteandsuccessofourstrategictransactions;ourtimelinefor\nfilingINDsandotherregulatoryfilings,andseekingregulatoryapproval,foroneormoreofourcurrentorfutureprogramsandproductcandidatesandotheranticipatedmilestones;ourexpectedcashrunway;ourabilitytoexpandourplatformandestablishabroadpipelineand\nadvanceitthroughefficientclinicaldevelopmentdecisions;ourintentiontocontinueexpandingourpipelinethroughstrategictransactions;ourintenttoexpandourintellectualpropertyportfolio;andotherstatementsregardingmanagement’sintentions,plans,beliefs,\nexpectationsorforecastsforthefuture.Theseforward-lookingstatementsarebasedonImmunome’scurrentexpectationsandinvolveassumptionsthatmaynevermaterializeormayprovetobeincorrect;consequently,actualresultsmaydiffermateriallyfromthoseexpressed\norimpliedinthestatementsduetoanumberoffactors,including,butnotlimitedto,theriskthatImmunomewillnotbeabletorealizethebenefitsofitsstrategictransactions;theriskthatregulatoryapprovalsforImmunome’sprogramsandproductcandidatesarenotobtained,\naredelayedoraresubjecttounanticipatedconditions;theriskthatpre-clinicaldatamaynotbepredictiveofclinicaldata;theriskthatImmunome’sproductcandidatesanddevelopmentcandidatesfailtoachievetheirintendedendpoints;therelianceonImmunome’s\nmanagement;thepriorexperienceandsuccessesofImmunome’smanagementteamnotbeingindicativeofanyfuturesuccess;uncertaintiesrelatedtoImmunome’scapitalrequirementsandImmunome’sexpectedcashrunway;Immunome’sabilitytogrowandsuccessfully\nexecuteonitsbusinessplan,includingthedevelopmentandcommercializationofitspipelineandintegrationofnewlyacquiredassets;andotherrisksanduncertaintiesindicatedfromtimetotimedescribedinImmunome’sQuarterlyReportonForm10-Qforthequarterended\nMarch31,2024,filedwiththeSEConMay14,2024,inImmunome’sQuarterlyReportonForm10-QforthequarterendedJune30,2024,filedwiththeSEConAugust12,2024,andinImmunome’sotherfilingswiththeSEC.Exceptasrequiredbylaw,Immunomeassumesno\nobligationanddoesnotintendtoupdateanyforward-lookingstatementsincludedinthispresentation.\nProductCandidates\nInthispresentation,wemaydiscusscurrentandpotentialfutureproductcandidatesthathavenotyetundergoneclinicaltrialsorbeenapprovedformarketingbytheU.S.FoodandDrugAdministrationorothergovernmentalauthority.Norepresentationismadeastothesafety\noreffectivenessofthesecurrentorpotentialfutureproductcandidatesfortheuseforwhichsuchproductcandidatesarebeingstudied.\nIndustryandMarketData\nInthispresentation,werelyonandrefertopubliclyavailableinformationandstatisticsregardingmarketparticipantsinthesectorsinwhichwecompeteandotherindustrydata.Anycomparisonofustotheindustryortoanyofourcompetitorsisbasedonthispubliclyavailable\ninformationandstatisticsandsuchcomparisonsassumethereliabilityoftheinformationavailabletous.Weobtainedthisinformationandstatisticsfromthird-partysources,includingreportsbymarketresearchfirmsandcompanyfilings.Whilewebelievesuchthird-party\ninformationisreliable,therecanbenoassuranceastotheaccuracyorcompletenessoftheindicatedinformation.Wehavenotindependentlyverifiedtheinformationprovidedbythethird-partysources.\nTrademarks\nThispresentationmaycontaintrademarks,servicemarks,tradenamesandcopyrightsofothercompanies,whicharethepropertyoftheirrespectiveowners.Solelyforconvenience,someofthetrademarks,servicemarks,tradenamesandcopyrightsreferredtointhis\npresentationmaybelistedwithouttheTM,SM©or®symbols,butwewillassert,tothefullestextentunderapplicablelaw,therightsoftheapplicableowners,ifany,tothesetrademarks,servicemarks,tradenamesandcopyrights.\nIMMUNOME 2\nEstablishing a Premier Targeted Oncology Company\nSSttrroonngg FFoouunnddaattiioonn ffoorr LLoonngg--TTeerrmm SSuucccceessss LLoonngg TTeerrmm CCoorrppoorraattee VViissiioonn\n•• EExxppeerriieenncceedd,, ssuucccceessssffuull lleeaaddeerrsshhiipp tteeaamm\n•• DDeevveelloopp ffiirrsstt--iinn--ccllaassss aanndd bbeesstt--iinn--ccllaassss oonnccoollooggyy tthheerraappiieess\n•• FFuullllyy eennrroolllleedd PPhhaassee 33 ttrriiaall ooff AALL110022 ffoorr tthhee ttrreeaattmmeenntt ooff\n•• OOrrggaanniicc ppiippeelliinnee eexxppaannssiioonn ddrriivveenn bbyy iinntteerrnnaall ddiissccoovveerryy\nddeessmmooiidd ttuummoorrss\npprrooggrraammss\n•• TTwwoo pprreecclliinniiccaall pprrooggrraammss wwiitthh ffiirrsstt--iinn--ccllaassss oorr bbeesstt--iinn--ccllaassss\n•• AAddddiittiioonnaall ppllaattffoorrmm aanndd ppiippeelliinnee eexxppaannssiioonn ddrriivveenn bbyy\nppootteennttiiaall:: ddiisscciipplliinneedd MM&&AA\n•• IIMM--11002211:: RROORR11 aannttiibbooddyy--ddrruugg ccoonnjjuuggaattee ((AADDCC))\n•• AAddvvaannccee ppiippeelliinnee tthhrroouugghh eeffffiicciieenntt cclliinniiccaall ddeevveellooppmmeenntt\n•• IIMM--33005500:: FFAAPP rraaddiioolliiggaanndd tthheerraappyy ((RRLLTT)) ddeecciissiioonnss\n•• TTaarrggeett--ddrriivveenn AADDCC aanndd RRLLTT ssttrraatteeggyy wwiitthh bbrrooaadd ttoooollbbooxx •• SSttrroonngg bbiiootteecchh iinnvveessttoorr ssyynnddiiccaattee ssuuppppoorrttiivvee ooff ccoorrppoorraattee\nvviissiioonn\n•• HHeeaaddqquuaarrtteerrss iinn BBootthheellll,, WWAA,, wwiitthh aa ccaappiittaall--eeffffiicciieenntt\nllaabboorraattoorryy iinn EExxttoonn,, PPAA •• SSttrraatteeggiicc ppaarrttnneerriinngg ttoo aacccceessss nnoonn--ddiilluuttiivvee ccaappiittaall\n•• CCaasshh rruunnwwaayy eexxppeecctteedd ttoo eexxtteenndd iinnttoo 22002266 ffoolllloowwiinngg rreecceenntt\nffiinnaanncciinnggss iinn FFeebbrruuaarryy 22002244 (($$223300MM)) aanndd OOccttoobbeerr 22002233\n(($$112255MM))\nIMMUNOME 3\nRecent Business Development Activity Expands Pipeline and Toolbox With\nModerate Investment\nEExxcclluussiivvee lliicceennssee ooff AADDCC aasssseettss PPuurrcchhaassee ooff AALL110022,, aa PPhhaassee 33 aasssseett ffoorr PPuurrcchhaassee ooff aasssseettss rreellaatteedd ttoo oovveerr 2255\nttrreeaattmmeenntt ooff ddeessmmooiidd ttuummoorrss pprreecclliinniiccaall aannttiibbooddiieess\n••PPrreecclliinniiccaall RROORR11 AADDCC wwiitthh bbeesstt--iinn--ccllaassss\nppootteennttiiaall\nDDaattaa ffrroomm cclliinniiccaall ttrriiaallss sshhooww AALL110022 mmaayy bbee OOppppoorrttuunniittyy ttoo ppuurrssuuee AADDCCss aaggaaiinnsstt nnoovveell oorr\n••DDiiffffeerreennttiiaatteedd AADDCC ppllaattffoorrmm tteecchhnnoollooggyy mmoorree eeffffeeccttiivvee iinn ttrreeaattiinngg ddeessmmooiidd ttuummoorrss uunnddeerreexxpplloorreedd ttaarrggeettss\ntthhaann OOGGSSIIVVEEOO™™((nniirrooggaacceessttaatt))\nPPootteennttiiaall ttoo aaddvvaannccee RROORR11 AADDCC iinn mmuullttiippllee FFiinnaanncciiaall tteerrmmss::\nssoolliidd ttuummoorr iinnddiiccaattiioonnss wwiitthh llaarrggee mmaarrkkeett FFuullllyy eennrroolllleedd PPhhaassee 33 RRIINNGGSSIIDDEE ttrriiaall,, wwiitthh\n••$$55..55 mmiilllliioonn iinn ccaasshh uuppffrroonntt\nssiizzee aaddddiittiioonnaall NNDDAA--eennaabblliinngg wwoorrkk uunnddeerrwwaayy\n••$$77 mmiilllliioonn iinn ddeevveellooppmmeenntt mmiilleessttoonneess\nOOppppoorrttuunniittyy ttoo ddeevveelloopp mmuullttiippllee pprrooggrraammss OOppppoorrttuunniittyy ttoo ppuurrssuuee aaddddiittiioonnaall iinnddiiccaattiioonnss\nwwiitthh pprroopprriieettaarryy lliinnkkeerr--ppaayyllooaadd uunniitt\nFFiinnaanncciiaall tteerrmmss::\nFFiinnaanncciiaall tteerrmmss::\n••$$3300 mmiilllliioonn iinn ssttoocckk aanndd $$2200 mmiilllliioonn iinn ccaasshh\n••$$3355 mmiilllliioonn uuppffrroonntt ((ccaasshh aanndd ssttoocckk)) uuppffrroonntt\n••$$227755 mmiilllliioonn iinn mmiilleessttoonneess ••$$3377..55 mmiilllliioonn iinn mmiilleessttoonneess\n••SSiinnggllee ddiiggiitt rrooyyaallttiieess\nIMMUNOME 4\nPipeline Overview\nMechanism of\nCandidate Discovery Preclinical Phase 1 Phase 2 Phase 3 Next Anticipated Milestone\nAction\nGamma Secretase Phase 3 Topline\nAL102\nInhibitor 2H25\nIND Submission\nIM-1021 ROR1 ADC\n1Q25\nIND Submission\nIM-3050 FAP RLT\n1Q25\n- Undisclosed ADCs TBD\n- Undisclosed RLTs TBD\nIM-1021 was formerly known as ZPC-21.\nIMMUNOME 5\nADC Strategy\nIMMUNOME 6\nTarget-Driven Development For the Next Generation of ADCs\nEstablish a broad pipeline and advance it through efficient clinical development decisions\nIImmmmuunnoommee AADDCC AApppprrooaacchh Systematic Development Through\nClinical Proof of Concept\n•• FFooccuuss oonn oonnccoollooggyy iinnddiiccaattiioonnss wwiitthh hhiigghh uunnmmeett nneeeedd\n•• IIddeennttiiffyy nnoovveell oorr uunnddeerreexxpplloorreedd ttaarrggeettss tthhaatt aarree ssuuiittaabbllee ffoorr\nAADDCCss aanndd aaddvvaannccee ffiirrsstt--iinn--ccllaassss ccoommppoouunnddss OOppttiimmiizzaattiioonn ffoorr bbiinnddiinngg && iinntteerrnnaalliizzaattiioonn\n•• IIddeennttiiffyy cclliinniiccaallllyy vvaalliiddaatteedd ttaarrggeettss wwhheerree eexxiissttiinngg pprrooggrraammss\nsshhooww lliimmiittaattiioonnss aanndd aaddvvaannccee bbeesstt--iinn--ccllaassss AADDCCss\nIInnccoorrppoorraattiioonn ooff pprroovveenn oorr nnoovveell lliinnkkeerrss\n•• DDeeeeppllyy uunnddeerrssttaanndd ttaarrggeett bbiioollooggyy\n•• DDeeppllooyy bbrrooaadd ttoooollbbooxx ooff aannttiibbooddiieess,, lliinnkkeerrss,, aanndd ppaayyllooaaddss ttoo\nSSeelleecctt ppaayyllooaadd ffoorr ccoonnssiisstteenntt ccyyttoottooxxiicc eeffffeecctt\nmmaattcchh ttaarrggeett bbiioollooggyy\nOOppttiimmiizzee pphhaarrmmaaccoollooggyy ffoorr cclliinniiccaall aaccttiivviittyy\nEEaarrllyy ggoo//nnoo--ggoo ddeecciissiioonnss vviiaa wweellll--ddeessiiggnneedd cclliinniiccaall ttrriiaallss\nIMMUNOME 7\nADC Activity is Concentrated in a Small Number of Targets\nTToopp 1100 TTaarrggeettss AAccccoouunntt ffoorr 5544%% ooff AAccttiivvee CClliinniiccaall DDoowwnnssiiddeess ooff PPuurrssuuiinngg MMoosstt PPooppuullaarr TTaarrggeettss\nAADDCC PPrrooggrraammss\n•• LLiimmiittaattiioonnss ooff eexxiissttiinngg ddrruuggss mmaayy bbee ddiiffffiiccuulltt ttoo oovveerrccoommee\n•• PPeerrffoorrmmaannccee ooff ccuurrrreenntt ddrruuggss mmaayy bbee lliimmiitteedd bbyy hheetteerrooggeenneeiittyy ooff ttaarrggeett\neexxpprreessssiioonn oonn ttuummoorrss\n•• CChhaannggeess iinn ppaayyllooaadd aanndd lliinnkkeerr tteecchhnnoollooggyy aarree lliikkeellyy ttoo mmaakkee oonnllyy\niinnccrreemmeennttaall ggaaiinnss\n•• CChhaalllleennggiinngg ddeevveellooppmmeenntt aanndd ccoommmmeerrcciiaalliizzaattiioonn ppaatthh\n•• LLoowweerr uunnmmeett ppaattiieenntt nneeeedd\n34\n17\n15\n10\n8 8 8\n6\n4 4\nIMMUNOME 8\nsmargorP\nCDA\nlacinilC\nevitcA\nIdentifying appropriate targets is a key challenge of ADC development\nApproved ADC\nNo Approved ADC\n1.: Immunome Analysis of Beacon ADC data. from Hanson Wade as of November 10, 2023\nIMMUNOME 9\nnoisserpxE\nromuT\nSystematically Evaluate Novel Targets for First-in-Class ADC Potential\nTargets are evaluated for differential tumor\nSources of Novel Targets and Antibodies expression and additional considerations\nSolid Tumor ADCs\nImmunome Discovery Platform\nTivdak\n>30 identified targets\nTrodelvy\nLicensing/Acquisition\n>25 antibodies from Atreca Elahere\nExpression Screening Enhertu,\nPadcev Kadcyla\nPublic and proprietary databases\nApproved Drugs\nClinical Stage Programs\nImmunome Internal Targets\nNormal Tissue Expression\nProprietary Payload Provides Opportunity to Develop Best-in-Class ADCs\nPPrroopprriieettaarryy AADDCC PPaayyllooaadd\n•• CCaammppttootthheecciinnddeerriivvaattiivvee//TTOOPPOO11 iinnhhiibbiittoorr\n•• SSaammee ccllaassss aass EEnnhheerrttuuppaayyllooaadd ddeerruuxxtteeccaann((DDXXdd))\n•• DDeevveellooppeedd bbyy ZZeennttaalliiss aanndd eexxcclluussiivveellyy lliicceennsseedd ttoo IImmmmuunnoommee Vehicle control, i.v., QWx3\n3000\nHer2-3-DXd (Enhertu), 3mg/kg, i.v., QWx3 •• DDeessiiggnneedd ttoo hhaavvee eennhhaanncceedd AADDMMEE pprrooppeerrttiieess ccoommppaarreedd\n2500 ttoo DDXXdd Her2-3-DXd (Enhertu), 10mg/kg, i.v.,\nQWx3w\n•• GGrreeaatteerr iinn vviittrroo ppootteennccyy Her2-1-5379, 3mg/kg, i.v., QWx3\n2000\n•• IInnccrreeaasseedd ppeerrmmeeaabbiilliittyy mmaayy lleeaadd ttoo ssuuppeerriioorr bbyyssttaannddeerr eeffffeecctt Her2-1-5379, 10mg/kg, i.v., QWx3\n•• FFaasstteerr cclleeaarraannccee mmaayy iimmpprroovvee ttoolleerraabbiilliittyy aafftteerr cclleeaavvaaggee 1500\n1000\nDXd IMNM Payload\nEC 11.6 nM 8.3 nM 500\n50\nPAMPA (Permeability) 21.9 * 10-6cm/s 69.0 * 10-6cm/s\n0\nHuman hepatocyte intrinsic\n148 min 51.1 min 0 7 14 21 28 35 42 49\nclearance T\n1/2\nStudy Day\nIMMUNOME 10\n)³mm(\nemuloV\nromuT\nWhen conjugated to the same antibody, IMNM payload shows improved efficacy compared to DXd\nHER2 ADC Constructed with IMNM\nProprietary Payload Outperforms Enhertu\nin JIMT-1 Breast Cancer Model\nVehicle\nHER2-DXd (Enhertu), 3mg/kg\nHER2-DXd (Enhertu), 10mg/kg\nHER2-IMNM Payload, 3mg/kg\nHER2-IMNM Payload, 10mg/kg\nAll arms of JIMT-1 study dosed QWx3\nCamptothecin Derivatives Are Well-Suited for ADCs Targeting Solid Tumors\nAADDCCss CCoonnttaaiinniinngg CCaammppttootthheecciinnss AAcchhiieevvee HHiigghheerr EEnnhheerrttuu ((WWiitthh CCaammppttootthheecciinn DDeerriivvaattiivvee PPaayyllooaadd))\nDDAARRss aanndd HHiigghheerr CClliinniiccaall DDoosseess OOuuttppeerrffoorrmmss KKaaddccyyllaa iinn BBrreeaasstt CCaanncceerr33\n12\n10\n8\n6\n10\n4\n5.4\n2 3.6\n1.8 1.25 2 2.5\n0\nPolivy® Padcev® Tivdak® Kadcyla® MK-2140 Enhertu® Trodelvy®\nIMMUNOME 11\n)gk/gm(\nesod\nlacinilC\nClinical Doses of Selected ADCs1\nPayload MOA\nMicrotubule Inhibitor\nTOPO1 Inhibitor (TOPO1i)\n10\n8\n6\n• Enhertuand Kadcyla are both trastuzumab ADCs\n4 8 7.6 • Enhertu’spayload, deruxtecan, allows for higher DAR and higher\n2 3.5 3.8 4 3.5 4 clinical dosage\n• Clinical data shows Enhertuis more effective, notably in HER2-\n0\nPolivy® Padcev® Tivdak® Kadcyla® MK-2140 Enhertu® Trodelvy® low patients\nRAD\nProgression-Free Survival\nEnhertu\n(Trastuzumab deruxtecan)\nn=261\nKadcyla\n(Trastuzumab emtansine)\nDrug-Antibody Ratios of Selected ADCs2 n=263\nPayload MOA\nMicrotubule Inhibitor\nTOPO1 Inhibitor (TOPO1i)\n1. Respective drug labels or FDA guidance 2. Tong JTW, Harris PWR, Brimble MA, KavianiniaI. An Insight into FDA Approved Antibody-Drug Conjugates for Cancer Therapy. Molecules. 2021 Sep 27;26(19):5847. doi: 10.3390/molecules26195847. PMID: 34641391; PMCID:\nPMC8510272. 3. Cortés et. al. N EnglJ Med (2022); 386:1143-1154\nstneitap\nfo\negatnecreP\nStrong Demand for ADCs Provides Strategic Flexibility\nOpportunities to Transact at Value Inflection Points\n$$22BB $$117700MM $$44BB\nTTOOTTAALL11 UUPPFFRROONNTT33 UUPPFFRROONNTT\n$$11..55BB++ $$2222BB\nIINN MMIILLEESSTTOONNEESS IINN MMIILLEESSTTOONNEESS55\n$$4433BB\nAACCQQUUIISSIITTIIOONN77\n$$117755MM $$8855MM $$22BB\nUUPPFFRROONNTT UUPPFFRROONNTT44 AACCQQUUIISSIITTIIOONN66\n$$99..33BB22 $$11..44BB\nIINN MMIILLEESSTTOONNEESS IINN MMIILLEESSTTOONNEESS\nPRECLINICAL EARLY CLINICAL LATE CLINICAL COMMERCIAL\n1. https://synaffix.com/synaffix-enters-license-agreement-with-amgen-to-build-next-generation-adcs 2.. https://www.biospace.com/article/merck-expands-adc-footprint-with-9-3b-kelun-licensing-deal 3. https://www.globenewswire.com/news-release/2023/04/03/2639380/0/en/BioNTech-and-DualityBio-Form-Global-Strategic-Partnership-to-Accelerate-Development-of-Differentiated-Antibody-Drug-\nConjugate-Therapeutics-for-Solid-Tumors.html 4. https://www.fiercebiotech.com/biotech/2nd-big-adc-deal-day-gsk-inks-2b-pact-hansoh-gynecology-cancer-asset 5. https://www.fiercebiotech.com/biotech/merck-pays-4b-upfront-rights-3-daiichi-adcs-huge-bet-post-keytruda-future 6. https://www.globenewswire.com/news-release/2024/01/08/2805344/0/en/Ambrx-Announces-Sale-to-Johnson-\nJohnson.html7. https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invests-43-billion-battle-cancer\nIMMUNOME 12\nSNOITCASNART\nCDA\nTNECER\nAL102\nIMMUNOME 13\nHigh Unmet Need for Patients with Desmoid Tumors\nDDeessmmooiidd TTuummoorrss AArree DDeebbiilliittaattiinngg,, PPaaiinnffuull,, aanndd GGaammmmaa SSeeccrreettaassee IInnhhiibbiittoorrss FFoorr TTrreeaattmmeenntt ooff\nAAggggrreessssiivvee DDeessmmooiidd TTuummoorrss\n•• GGaammmmaa sseeccrreettaassee iinnhhiibbiittoorrss ((GGSSIIss)) bblloocckk tthhee NNOOTTCCHH\n~1,000-1,650 ~5,500-7,000\nppaatthhwwaayy,, aa ddrriivveerr ooff ddeessmmooiidd ttuummoorrss\nPatients diagnosed Actively managed patients\nannually in the US1 in the US2 •• OOGGSSIIVVEEOO ((nniirrooggaacceessttaatt)),, aa GGSSII ffrroomm SSpprriinnggwwoorrkkss,, wwaass\naapppprroovveedd iinn NNoovveemmbbeerr 22002233 ffoorr ttrreeaattmmeenntt ooff ddeessmmooiidd ttuummoorrss\n•• PPaaiinnffuull ssoofftt ttiissssuuee ttuummoorrss tthhaatt ccaann lleeaadd ttoo sseerriioouuss ddiissaabbiilliittyy\nwwhheenn lleefftt uunnttrreeaatteedd\n•• HHiigghheesstt iinncciiddeennccee iinn yyoouunngg aadduullttss,, wwiitthh wwoommeenn aatt ggrreeaatteerr rriisskk\ntthhaann mmeenn\n•• UUnnttiill 22002233,, nnoo aapppprroovveedd ssyysstteemmiicc tthheerraappyy;; llooccaall tthheerraappiieess aarree\nddeebbiilliittaattiinngg aanndd hhaavvee aa hhiigghh rriisskk ooff rreeccuurrrreennccee\n•• RReevveerrssiinngg ttuummoorr ggrroowwtthh,, aalllleevviiaattiinngg ppaaiinn,, aanndd pprreevveennttiinngg\ntthheerraappeeuuttiicc ccoommpplliiccaattiioonnss aarree kkeeyy ccoommppoonneennttss ooff tthheerraappeeuuttiicc\niinntteerrvveennttiioonn\n1. Gounder2023 doi: 10.1007/s11136-023-03445-7 2. Tsukamoto 2022 doi: 10.1007/s12306-022-00738-x\nIMMUNOME 14\nAL102 Data With Daily Dosing Shows Increased Response Compared to\nNirogacestat Across All Measures\nORR by RECIST\n•• AALL110022 iiss bbeeiinngg eevvaalluuaatteedd aass aann oorraall,, oonnccee--\nEvaluable\nddaaiillyy GGSSII ffoorr tthhee ttrreeaattmmeenntt ooff ddeessmmooiidd ttuummoorrss\nAL1021.2mgQD1\n75% ITT\nMedianToT16.6months\n•• PPhhaassee 22 RRIINNGGSSIIDDEE ddaattaa hhaass sshhoowwnn ddeeeepp,,\n64%\ndduurraabbllee rreessppoonnsseess aanndd aann ooppppoorrttuunniittyy ttoo Nirogacestat150mgBID2,3\neessttaabblliisshh nneeww ssttaannddaarrdd ooff ccaarree,, iiff aapppprroovveedd MedianToT20.6months\n44%\n41%\n•• RReedduucceedd TT22 iimmaaggiinngg ssuuggggeessttss rreedduucceedd\ncceelllluullaarriittyy\nTumorVolume T2 Imaging\n•• SSaaffeettyy pprrooffiillee ccoonnssiisstteenntt wwiitthh GGSSII ccllaassss N=12 N=66 N=14 N=70 (medianbest, evaluable) (medianbest, evaluable)\n•• PPhhaassee 33 RRIINNGGSSIIDDEE ttrriiaall ffuullllyy eennrroolllleedd,, wwiitthh N=12 N=61 N=12 N=53\naaddddiittiioonnaall NNDDAA--eennaabblliinngg wwoorrkk uunnddeerrwwaayy FOR ILLUSTRATIVE PURPOSES ONLY: no head-to-head clinical trial has been\nconducted evaluating AL102 against nirogacestat or other candidates or products.\nDifferences exist between trial designs and subject characteristics, and strong\ncaution should be exercised when comparing data across unrelated studies.\n-55%\n-59%\n-88% -85%\n1KasperBetal.,ESMOCongress2023_1929P (Cutoff Date –July 5, 2023) One patient previously reported as PR at ESMO subsequently progressed prior to response confirmation. 2. GounderMetal.,NEJM2023, 388:898 3. AlcindorT.,etal.,ASCOAnnualMeeting 2023,Abstract#11514 EvaluablePopulation\nIMMUNOME 15\nSafety in Phase 2 Portion of RINGSIDE is consistent with GSI class\nStudy Population, n(%) AL102, 1.2mg QD, (n=14) Nirogacestat 150mg BID (n=69)\nAny Grade Grade ≥3 Any Grade Grade ≥3\nDiarrhoea 13 (92.8) 2 (14.3) 58 (84) 11 (16)\nNausea 8 (57.1) – 37 (54) 1 (1)\nFatigue 7 (50) – 35 (51) 2 (3)\nAlopecia 7 (50) – 13 (19) –\nDry skin 7 (50) – 11 (16) –\nStomatitis 7 (50) 1 (7.1) 20 (29) 3 (4)\nDermatitis acneiform 6 (42.9) – 15 (22) –\nDry mouth 6 (42.9) – NR NR\nHypophosphatemia 6 (42.9) – 29 (42) 2 (3)\nRash maculo-papular 5 (35.7) – 22 (32) 4 (6)\nAspartate aminostransferase increased 4 (28.6) – 11 (16) –\nMonths on the study (mean, range), months 16.6 (1-21.6) 20.6 (0.3 –33.6)\nOvarian dysfunction in pre-menopausal women: 5/9 (55.6%) with AL102 in 1.2 mg QD arm versus 27/36 (75.0%) in Niro DeFi Study\nFOR ILLUSTRATIVE PURPOSES ONLY: no head-to-head clinical trial has been conducted evaluating AL102 against nirogacestat or othercandidates or products. Differences exist between trial designs and subject characteristics, and strong caution should be exercised when comparing data across unrelated studies.\n1KasperBetal.,ESMOCongress2023_1929P (Cutoff Date –July 5, 2023) 2. GounderMetal.,NEJM2023, 388:898 3. AlcindorT.,etal.,ASCOAnnualMeeting 2023,Abstract#11514 EvaluablePopulation\nIMMUNOME 16\nRINGSIDE study design: Phase 3\nPART B\nKey Inclusion Criteria Endpoints\n•Relapsed/refractory or treatment- •Primary: PFS\nnaïve, with PD (per RECIST)\n•Secondary: ORR & DOR by BICR,\nin last 12 months\nPROs, Safety\n•Age ≥12\n•Exploratory: MRI T1 & T2, ORR &\n•Measurable Lesion or MRI or CT DOR by investigator, PK, Biomarkers\nOLE\nKey Inclusion Criteria Endpoints\n•Participating in Part B and were •Primary: Safety\nnoted to have progressive disease\n•Secondary: PFS, ORR & DOR by\nby central review\nBICR, PROs\n•Still on study after completion of\n•Exploratory: PK\nCrossover has no observed impact on statistical analysis Part B\nof primary endpoint\nIMMUNOME 17\nPrograms: ROR1 ADC\nIMMUNOME 18\nROR1 Is a Clinically Validated ADC Target\nRROORR11 MMKK--22114400 OObbjjeeccttiivvee RReessppoonnssee RRaattee IInn TThhrreeee\nPPrreettrreeaatteedd LLyymmpphhoommaa IInnddiiccaattiioonnss\n•• RReecceeppttoorr wwiitthh oonnccooffeettaall eexxpprreessssiioonn ppaatttteerrnn11\n•• LLiittttllee oorr nnoo eexxpprreessssiioonn iinn hheeaalltthhyy ttiissssuuee\n•• EExxpprreesssseedd oonn ssoolliidd aanndd lliiqquuiidd ttuummoorrss 60%\n50% 14%\n12%\nMMKK--22114400\n40%\n•• MMKK--22114400 ((ffoorrmmeerrllyy kknnoowwnn aass VVLLSS--110011)) iiss aa RROORR11--ttaarrggeetteedd\nAADDCC 30%\n•• MMeerrcckk aaccqquuiirreedd VVeellooss BBiioo ffoorr $$22..7755 bbiilllliioonn ttoo oobbttaaiinn VVLLSS--110011 20% 18% 41% 43%\n•• CCuurrrreennttllyy bbeeiinngg eevvaalluuaatteedd iinn ffoouurr pphhaassee 22 ttrriiaallss ffoorr\n10%\nBB--cceellll mmaalliiggnnaanncciieess\n12%\n0%\n•• DDeevveellooppmmeenntt ffoorr ssoolliidd ttuummoorrss ddiissccoonnttiinnuueedd aafftteerr PPhhaassee 22\nDiffuse Large B-Cell Mantle Cell Richter's\nLymphoma Lymphoma Transformation\n(n=17) (n=17) (n=7)\nIMMUNOME 19\nRRO\nPR CR\n1. Hojjat-Farsangi M, Moshfegh A, Daneshmanesh AH, Khan AS, Mikaelsson E, Osterborg A, Mellstedt H. The receptor tyrosine kinase ROR1--an oncofetal antigen for targeted cancer therapy. Semin Cancer Biol. 2014 Dec;29:21-31. doi: 10.1016/j.semcancer.2014.07.005. Epub 2014 Jul 25. PMID: 25068995 2.Wang, et al. HematOncol, 41:S2, Lugano\nLymphoma Conference Supplement Supplement: 17th International Conference on Malignant Lymphoma, 13 -17 June, 2023\nSignificant Opportunity for ROR1 in Solid Tumors\nPPootteennttiiaall RROORR11 iinnddiiccaattiioonnss iinncclluuddee ddiisseeaasseess wwiitthh RROORR11 ttaarrggeett bbiioollooggyy pprreesseennttss cchhaalllleennggeess ttoo\nllaarrggee ppaattiieenntt ppooppuullaattiioonn aanndd hhiigghh uunnmmeett nneeeedd ddeevveellooppiinngg aa ssuucccceessssffuull AADDCC ffoorr RROORR11 ppoossiittiivvee\nssoolliidd ttuummoorrss\n100%\n•• MMooddeerraattee ttoo llooww eexxpprreessssiioonn lleevveellss\n90%\n•• SSllooww iinntteerrnnaalliizzaattiioonn\n80%\n70% AApppprrooaacchh ttoo oovveerrccoommee cchhaalllleennggeess\n60%\n•• SSeelleecctt aannttiibbooddyy tthhaatt pprroommootteess iinntteerrnnaalliizzaattiioonn\n50%\n40% •• DDeessiiggnn lliinnkkeerr--ppaayyllooaadd ffoorr iimmpprroovveedd tthheerraappeeuuttiicc iinnddeexx,, aalllloowwiinngg\n30% ffoorr hhiigghheerr cclliinniiccaall ddoossee\n20%\n•• UUssee ppaayyllooaadd tthhaatt mmaaxxiimmiizzeess bbyyssttaannddeerr eeffffeecctt aanndd ssuuppppoorrttss\n10%\nddrruugg--aannttiibbooddyy rraattiioo ((DDAARR)) ooff 88\n0%\n1. Wang, et al. HematOncol, 41:S2, Lugano Lymphoma Conference Supplement Supplement: 17th International Conference on Malignant Lymphoma, 13 -17 June, 2023\nIMMUNOME 20\n)441=n(\nnairavO\n)011=n(\nnoloC\n)46=n(\ngnuL\n)85=n(\namohpmyL\n)55=n(\nnikS\n)75=n(\ncitaercnaP\n)84=n(\nralucitseT\n)04=n(\nreddalB\n)92=n(\nsuretU\n)12=n(\netatsorP\n)21=n(\nlanerdA\nPercent of\nROR1\nPositive\nNegative\nModerate\nStrong\nIM-1021 is a ROR1 ADC with Potential for Improved Therapeutic Index\nZilovertamabVedotin(MK-2140 / VLS-101) MC-VC-PAB MMAE: Tubulin Inhibitor Phase 2 completed;\nno further updates\nCysteine conjugation\nCleavable through Val-Cit\nDAR 4\nNBE-002 Peptide linker containing GGGG PNU (Anthracycline derivative): Discontinued\nDNA intercalator\nSortase-mediated conjugation\nCleavable\nDAR 4\nCS5001 (LCB71) Glucuronidase cleavable linker Pyrrolobenzodiazepine Phase 1 Ongoing\n(PBD-dimer) prodrug: DNA\nFarnesyltransferase conjugation\ncrosslinker\nCleavable\nDAR 2\nIM-1021 (Formerly ZPC-21) Undisclosed linker CamptothecinDerivative: IND expected 1Q 2025\nCysteine conjugation Topoisomerase I inhibitor\nStructure Omitted Cleavable\nDAR 8\nIMMUNOME 21\nMIVC\nName Linker / DAR Payload Development Status\nIIMM--11002211 IInnhhiibbiittss TTuummoorr GGrroowwtthh iinn MMDDAA--MMBB--446688 NNoo WWeeiigghhtt LLoossss OObbsseerrvveedd\nMMooddeell ((TTrriippllee NNeeggaattiivvee BBrreeaasstt CCaanncceerr))\nIMMUNOME 22\n)3mm(\nemuloV\nromuT\nIM-1021 Shows Sustained Tumor Regression in TNBC Mouse Model\negnahC\nWB\n%\nIM-1021 demonstrates superior activity compared to MK-2140 at each respective dose\nDose QWx3, i.v.\nClinical Development Plan: Rapid Evaluation of Clinical PoC Followed by\nPivotal Studies Across Multiple Indications\nPPiivvoottaall CClliinniiccaall SSttuuddiieess\nSSoolliidd ttuummoorr eexxppaannssiioonn\nIInnddiiccaattiioonnss iinncclluuddiinngg NNSSCCLLCC,, bbrreeaasstt •• CCrriitteerriiaa ffoorr sseelleeccttiinngg iinnddiiccaattiioonnss\nccaanncceerr,, pprroossttaattee ccaanncceerr,, ppaannccrreeaattiicc\nccaanncceerr,, aanndd ggaassttrriicc ccaanncceerr11 •• CCoommppeelllliinngg PPhhaassee 11 cclliinniiccaall\noouuttccoommeess\nRRaappiidd ddoossee eessccaallaattiioonn iinn\nssoolliidd ttuummoorrss aanndd llyymmpphhoommaa •• SSiiggnniiffiiccaanntt ccoommmmeerrcciiaall\nooppppoorrttuunniittiieess\nBB--cceellll mmaalliiggnnaannccyy eexxppaannssiioonn\n•• EEnnhhaanncceedd oouuttccoommeess wwiitthh\nDDiiffffuussee llaarrggee BB--cceellll llyymmpphhoommaa,, mmaannttllee\nccoommppaanniioonn ddiiaaggnnoossttiicc\ncceellll llyymmpphhoommaa\n•• PPootteennttiiaall ffoorr AAcccceelleerraatteedd AApppprroovvaall\nNNoonn--cclliinniiccaall eevvaalluuaattiioonn ooff ccoommbbiinnaattiioonn tthheerraappiieess,, ppaarrttiiccuullaarrllyy iinn BB--cceellll mmaalliiggnnaanncciieess\nCCoommppaanniioonn ddiiaaggnnoossttiicc ddeevveellooppmmeenntt aanndd eevvaalluuaattiioonn\n1. Clinical development plan subject to further refinement and addition or removal of indications.. NSCLC = non-small cell lung cancer\nIMMUNOME 23\nPrograms: FAP RLT\nIMMUNOME 24\nFAP Is a Promising RLT Target with Pan-Cancer Potential\nFFiibbrroobbllaasstt AAccttiivvaattiioonn PPrrootteeiinn ((FFAAPP)) iiss aa cceellll ssuurrffaaccee FFAAPP iimmaaggiinngg sshhoowwss hhiigghh eexxpprreessssiioonn aaccrroossss\npprrootteeaassee wwiitthh llooww eexxpprreessssiioonn iinn nnoorrmmaall ttiissssuuee 1155 ddiissttiinncctt ttuummoorr ttyyppeess\n•• FFAAPP iiss oovveerreexxpprreesssseedd oonn ccaanncceerr--aassssoocciiaatteedd ffiibbrroobbllaassttss,, tthhee\nmmoosstt ccoommmmoonn ttuummoorr ssttrroommaall cceellll,, wwiitthh eexxpprreessssiioonn iinn 7755%% ooff\nssoolliidd ttuummoorrss\n•• FFAAPP--LLuu rraaddiioolliiggaanndd tthheerraappyy ddeelliivveerrss rraaddiiooaaccttiivvee 117777LLuu ddiirreeccttllyy\nttoo FFAAPP--eexxpprreessssiinngg cceellllss,, wwiitthh bbyyssttaannddeerr eeffffeecctt ttaarrggeettiinngg ttuummoorr\ncceellllss\n•• RRLLTT aapppprrooaacchh eexxppeecctteedd ttoo oovveerrccoommee lliimmiittaattiioonnss tthhaatt mmaakkee FFAAPP\nuunnssuuiittaabbllee ffoorr AADDCCss ((ppoooorr iinntteerrnnaalliizzaattiioonn aanndd llooww eexxpprreessssiioonn oonn\nttuummoorr cceellllss))\nSource: Kratochwil C, Flechsig P, Lindner T, et al.68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer.J Nucl Med.2019;60(6):801-805.\nIMMUNOME 25\nImmunome 177Lu-FAP Candidates are Rationally Designed and\nSystematically Screened\nImmunome Approach\nImmunome has systematically selected Example Structure: PPrroovveenn ssttrruuccttuurree uusseedd bbyy\nPPlluuvviiccttoo aanndd LLuuttaatthheerraa ttoo\na ligand, linker, albumin binding OOppttiimmiizzeedd lliinnkkeerr ddeelliivveerr LLuu--117777 iissoottooppee\nrreedduucceess nnoonn--ssppeecciiffiicc\ndomain, and payload to optimize: uuppttaakkee\nFAP Ligand Chelator\n• Binding and specificity\nLinker\n• Stability\n• Pharmacokinetics\n• Tumor absorbed dose\n• Efficacy Albumin Binder\n• Tolerability\nFAP binding Albumin binding domain selected to\nand specificity optimized maximize tumor retention\nOptimized ligand potentially leads to: Incorporating albumin binder potentially\n• Increased tumor uptake and retention extends circulating half-life and increases\ntumor residence time, leading to superior\n• Superior efficacy\ntumor absorbed dose in vivo\n• Stability and ease of manufacture\nIMMUNOME 26\nIncorporating Albumin Binders into Radioligand Therapies Improves In Vivo\nPK Profile and Biodistribution\nTToottaall AAbbssoorrbbeedd DDoossee RRaatt IIVV PPKK\n600 Albumin Binding\n500 Weak\nModerate\n400 Strong\n300\n200\n100\n0\nLiver Kidneys Tumor\nLeft panel: unpublished preclinical biodistribution data in 4T1 mouse tumor model. Right panel: Single dose (1 mg/kg) iv ratPKstudy.\nIMMUNOME 27\nqBM/yGm\n100000\n10000\n1000\n100\n10\n1\n0.1\n0 20 40 60\nTime (h)\nno\nintaoirttanrtencencnoocc\naammssaallPP\n)Lm/gn(\n)Lm/gn(\nEnhanced pharmacokinetics may lead to superior tumor absorbed dose\nAlbumin Binding\nWeak\nModerate\nStrong\nTime (Hours)\nIM-3050 is a 177Lu-FAP Candidate with Best-in-Class Potential\nTTuummoorr RReeggrreessssiioonn iinn UU8877MMGG MMooddeell NNoo WWeeiigghhtt LLoossss OObbsseerrvveedd PPootteennttiiaall BBeesstt--iinn--CCllaassss CChhaarraacctteerriissttiiccss\n SSuubb--nnaannoommoollaarr aaffffiinniittyy\n HHiigghh ssppeecciiffiicciittyy\n RRaaddiioossttaabbiilliittyy\n SSuuppeerriioorr ttuummoorr rreetteennttiioonn aanndd ttuummoorr\naabbssoorrbbeedd ddoossee iinn vviivvoo\n PPrreecclliinniiccaall aaccttiivviittyy aanndd ttoolleerraabbiilliittyy\nDEVELOPMENT STATUS:\n✓ ✓\nIn Vivo Radiotherapy Clinical Formulation IND filing\nGLP/GMP Manufacturing Prepare IND package\nStudies Development anticipated 1Q25\nIMMUNOME 28\nemulov\nromut\nevitaleR\nIn vivo data show single dose antitumor activity and tolerability\n177Lu-Mi-003 Radiotherapy in U87MG tumors\nVehicle VVeehhicilcele\nIM-3047, High Lu-177 Dose IUMn-d3is0cl4os7e,d HCaigndhid Latue- #117 (7H igDho Lsue-177 Dose)\nIM-3047, Low Lu-177 Dose IUMn-d3is0cl4os7e,d LCoanwd idLaute- 1#71 7(L oDwo Lsue-177 Dose)\nIM-3050, High Lu-177 Dose IUMn-d3is0cl5os0e,d HCaigndhid Latue- #127 (7H igDho Lsue-177 Dose)\nIM-3050, Low Lu-177 Dose 120% IUMn-d3is0cl5os0e,d LCoanwd idLaute- 1#72 7(L oDwo Lsue-177 Dose)\n110%\n100%\n90%\n80%\n70%\n0 3 6 9 12 15 18 21 24 27\nDay\nImmunome Discovery Platform\nIMMUNOME 29\nAntibody and Target Discovery Engine\nHarnessing the immune system to inform the next generation of cancer therapy\nPATIENT RESPONSES UNVEIL NOVEL DISEASE TARGETS\n01 02 03 04\nPPaattiieennttss wwiitthh ccaanncceerr ggeenneerraattee MMeemmoorryy BB cceellllss aarree iissoollaatteedd,, AAnnttiibbooddiieess aarree sseelleecctteedd uussiinngg NNoovveell aannttiibbooddyy--ttaarrggeett ppaaiirrss aarree\nmmeemmoorryy BB cceellllss tthhaatt pprroodduuccee aanndd iimmmmoorrttaalliizzeedd pprroopprriieettaarryy hhiigghh--tthhrroouugghhppuutt eevvaalluuaatteedd ffoorr ddeevveellooppmmeenntt aass\naauuttooaannttiibbooddiieess aaggaaiinnssttccaanncceerr-- uussiinnggpprroopprriieettaarryy hhyybbrriiddoommaa tteecchhnnoollooggyy wwiitthh ffuunnccttiioonnaall aanndd aannttiibbooddiieess,, bbiissppeecciiffiiccss,, oorr\naassssoocciiaatteedd aannttiiggeennss tteecchhnnoollooggyy,, ggeenneerraattiinngg nnoovveell sseeqquueennccee--bbaasseedd ssccrreeeennss AADDCCss\naannttiibbooddiieess\nAntibody Antibody-Target Pair\nPatient Tissue Sampling\nGeneration Identification\nIMMUNOME 30\nImmunome Approach Identifies Both Validated and Novel Cancer Target\nIIddeennttiiffiiccaattiioonn ooff CClliinniiccaallllyy VVaalliiddaatteedd CCaanncceerr TTaarrggeettss IImmmmuunnoommee TTeecchhnnoollooggyy EEnnhhaanncceess PPoowweerr\nVVaalliiddaatteess IImmmmuunnoommee AApppprrooaacchh ooff AAnnttiibbooddyy SSccrreeeennss\n•• MMeemmoorryy BB--cceellll rreessppoonnssee ggeenneerraatteedd aaccrroossss ccoouurrssee ooff ddiisseeaassee\n•• CCoommppeettiittoorr BB--cceellll ppllaattffoorrmmss rreessttrriicctt ssccooppee ttoo aaccttiivvee iimmmmuunnee rreessppoonnssee\n•• DDiirreecctt aannttiibbooddyy pprroodduuccttiioonn bbyy BB cceellllss ssuuppppoorrttss eexxtteennssiivvee,,\nuunnbbiiaasseedd ffuunnccttiioonnaall ssccrreeeenniinngg\n•• DDiiffffeerreenntt ssoouurrcceess ooff BB cceellllss ((llyymmpphh nnooddeess,, ttuummoorr,, bblloooodd)) mmaayy\nHER2 yyiieelldd uunniiqquuee ttaarrggeettss\n•• MMaatteerriiaallllyy eexxppaannddss ooppppoorrttuunniittyy ttoo iiddeennttiiffyy uunnddeerreexxpplloorreedd aanndd\nnnoovveell ttaarrggeettss\nTargets Identified by Discovery Engine\nIMMUNOME 31\nStrategic Discovery Collaboration with AbbVie\nKKeeyy FFiinnaanncciiaall TTeerrmmss\n•• AAbbbbVViiee ooppttiioonn ttoo ppuurrcchhaassee wwoorrllddwwiiddee rriigghhttss ffoorr uupp ttoo 1100\nnnoovveell ttaarrggeett--aannttiibbooddyy ppaaiirrss aarriissiinngg ffrroomm tthhrreeee ssppeecciiffiieedd\nttuummoorr ttyyppeess\n•• $$3300MM uuppffrroonntt ppaayymmeenntt\n•• EElliiggiibbllee ffoorr aaddddiittiioonnaall ppaayymmeennttss uupp ttoo::\n•• $$7700MM ppllaattffoorrmm aacccceessss ppaayymmeennttss ((iinn aaddddiittiioonn ttoo llooww ssiinnggllee--ddiiggiitt\nmmiilllliioonnss ppeerr ttaarrggeett ooppttiioonn ppaayymmeennttss))\n•• $$112200MM ppeerr ttaarrggeett ddeevveellooppmmeenntt aanndd ffiirrsstt ccoommmmeerrcciiaall ssaallee mmiilleessttoonneess\n•• $$115500MM ppeerr ttaarrggeett ffuurrtthheerr ssaalleess--bbaasseedd mmiilleessttoonneess\n•• TTiieerreedd rrooyyaallttiieess oonn gglloobbaall ssaalleess\nIMMUNOME 32\nIP, Business Development, and\nLeadership\nIMMUNOME 33\nProsecuting a Multi-Layered IP\nStrategy\nCOMPOSITION OF MATTER\n• Over 100 patents and patent\napplications across more than 20\nfamilies as of November 2023\n• Covers Immunome’s proprietary\nPLATFORM & DISCOVERY\nantibody sequences\n• Platform technologies and\n• Covers proprietary targeting\ndiscovery engines are protected\nligands and effectors, and lead\nusing a combination of patent\nconjugates for ligand-based\nfilings and trade secrets\ntherapy candidates\nIP EXPANSION OPPORTUNITY\n• Active ongoing research expected to generate additional company-\nowned trade secrets and patent filings around platforms and pipeline\n• Goodwin Procter and Morrison Foerster retained as IP counsel\nIMMUNOME 34\nManagement Team with a Demonstrated Track Record of Success\nClay Siegall, Ph.D. • Chief Executive Officer and Founder, Seagen (1998-2022)\nPRESIDENT & • Grew company to $2B+ revenue (2022) leading to $43B acquisition\nCHIEF EXECUTIVE OFFICER\n• Led development of 4 FDA-approved therapeutics\n• Raised over $1B in public and private capital\n• Oversaw acquisition and integration of Cascadian Therapeutics\n• Generated >$3B in partnership and licensing revenue\nJack Higgins, Ph.D. Kinney Horn Bob Lechleider, M.D. Max Rosett\nCHIEF SCIENTIFIC OFFICER CHIEF BUSINESS OFFICER CHIEF MEDICAL OFFICER CHIEF FINANCIAL OFFICER\nPhil Tsai Sandra Stoneman Bruce Turner, M.D., Ph.D.\nCHIEF TECHNICAL OFFICER CHIEF LEGAL OFFICER CHIEF STRATEGY OFFICER\nIMMUNOME 35\nBuilding the Foundation of a Premier Targeted Oncology Company\n• Experienced management team with headquarters in Bothell, WA\n• Fully enrolled Phase 3 trial for AL102 for the treatment of desmoid tumors\n• Two preclinical programs with best-in-class or first-in-class potential:\n• IM-1021: ROR1 ADC\n• IM-3050: FAP RLT\n• Opportunities for platform-driven pipeline expansion including next-generation ADCs and RLTs\n• Pipeline and toolbox expansion through disciplined M&A including recent purchase of AL102 from Ayala and exclusive\nlicense agreement with Zentalis\n• Cash runway expected to extend into 2026 and fund key clinical inflection points following recent financings in\nFebruary 2024 ($230M) and October 2023 ($125M)\nIMMUNOME 36"
        }
      ]
    }
  ]
}